4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding 4D Molecular Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 77 | 80 | +3 |
| Shares | 24.7M | 26.1M | +1.44M (+5.8%) |
| Value | $541.8M | $395.3M | −$146.5M (−27.0%) |
New holders (10)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 76,924 | $1.16M | 0.00% |
| Nisa Investment Advisors, LLC | 16,100 | $243.0K | 0.00% |
| Wetherby Asset Management Inc | 15,839 | $239.0K | 0.01% |
| Barclays PLC | 11,956 | $181.0K | 0.00% |
| Amalgamated Bank | 3,495 | $53.0K | 0.00% |
| Amalgamated Financial Corp. | 3,495 | $53.0K | 0.00% |
| Atlas Capital Advisors LLC | 675 | $10.2K | 0.00% |
| Prospera Financial Services Inc | 150 | $2.00K | 0.00% |
| Kayne Anderson Rudnick Investment Management LLC | 52 | $1.00K | 0.00% |
| CWM, LLC | 47 | $1.00K | 0.00% |
Sold out (7)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Woodline Partners LP | 132,117 | $2.90M |
| Jump Financial, LLC | 26,593 | $583.0K |
| Cubist Systematic Strategies, LLC | 17,913 | $393.0K |
| ProShare Advisors LLC | 10,626 | $233.0K |
| Royce & Associates LP | 9,300 | $204.0K |
| Marshall Wace, LLP | 3,317 | $73.0K |
| Group One Trading, L.P. | 242 | $5.00K |